Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated by Analysts at Brookline Capital Acquisition

Brookline Capital Acquisition initiated coverage on shares of Adial Pharmaceuticals (NASDAQ:ADIL) in a research note issued to investors on Wednesday morning, PriceTargets.com reports. The brokerage issued a buy rating and a $12.00 target price on the stock.

Other research analysts also recently issued reports about the stock. Maxim Group reaffirmed a buy rating and issued a $5.00 price objective on shares of Adial Pharmaceuticals in a report on Friday, August 20th. Litchfield Hills Research raised their price objective on shares of Adial Pharmaceuticals from $5.00 to $15.00 and gave the stock a buy rating in a report on Thursday, August 26th. Finally, Brookline Capital Management began coverage on shares of Adial Pharmaceuticals in a report on Wednesday. They issued a buy rating and a $12.00 price objective for the company.

Adial Pharmaceuticals stock opened at $4.10 on Wednesday. Adial Pharmaceuticals has a twelve month low of $1.60 and a twelve month high of $5.08. The firm has a 50 day moving average price of $3.85 and a 200-day moving average price of $2.95.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its earnings results on Wednesday, August 11th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.05).

A number of hedge funds and other institutional investors have recently bought and sold shares of ADIL. Dimensional Fund Advisors LP purchased a new stake in shares of Adial Pharmaceuticals during the 4th quarter valued at $32,000. Commonwealth Equity Services LLC raised its position in shares of Adial Pharmaceuticals by 107.3% during the 1st quarter. Commonwealth Equity Services LLC now owns 22,050 shares of the company’s stock valued at $53,000 after buying an additional 11,415 shares in the last quarter. Barclays PLC purchased a new stake in shares of Adial Pharmaceuticals during the 1st quarter valued at $38,000. Golden Green Inc. purchased a new stake in shares of Adial Pharmaceuticals during the 2nd quarter valued at $63,000. Finally, Oppenheimer & Co. Inc. raised its position in shares of Adial Pharmaceuticals by 93.1% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 28,000 shares of the company’s stock valued at $71,000 after buying an additional 13,500 shares in the last quarter. Institutional investors and hedge funds own 5.72% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Featured Story: Dead Cat Bounce

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.